XML 34 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Summary of Significant Accounting Policies  
Schedule of segment consolidated net loss, including significant segment expenses

The table below is a summary of the segment net loss, including significant segment expenses (in thousands):

THREE MONTHS ENDED

NINE MONTHS ENDED

SEPTEMBER 30, 

SEPTEMBER 30, 

2025

    

2024

    

2025

    

2024

Operating expenses:

  

  

  

  

Discovery research and development

$

24,602

$

17,417

$

72,633

$

37,809

Clinical research and development

28,647

11,811

68,953

29,507

Other research and development expenses

5,740

3,370

14,980

8,011

General and administrative

14,798

 

13,238

43,983

35,840

Total operating expenses

 

73,787

 

45,836

 

200,549

 

111,167

Loss from operations

 

(73,787)

 

(45,836)

 

(200,549)

 

(111,167)

Interest and other income, net

 

8,183

11,951

 

26,688

25,294

Loss before provision for income taxes

 

(65,604)

 

(33,885)

 

(173,861)

 

(85,873)

Provision for income taxes

 

108

92

 

345

174

Segment net loss and net loss attributable to ordinary shareholders

$

(65,712)

$

(33,977)

$

(174,206)

$

(86,047)